Partnerships in HPV Prevention High Sierra AHEC American Cancer Society

1. Partnerships in HPV Prevention High Sierra AHEC American Cancer Society Intermountain West HPV Coalition April 19, 2017

2. Closing the HPV Vaccination Gap: The Fundamentals of HPV for Oral Health Care Providers Presented By: Christina A. Demopoulos, DDS, MPH Diplomate, American Board of Dental Public Health Associate Professor, UNLV School of Dental Medicine High Sierra AHEC, American Cancer Society April 19, 2017

3. Background • UNLV undergrad • University of Southern California (USC) School of Dentistry • UNLV (Master of Public Health) • University of Texas, Health Science Center at San Antonio (UTHSCSA) [Dental Public Health Residency]

4. Learning Objectives • Describe the relationship between HPV and oropharyngeal cancer.  • Describe evidence-based strategies for increased awareness and prevention of HPV-related oropharyngeal cancer.  • Understand how community/clinical linkages can increase health promotion efforts regarding the HPV vaccine.  • Describe Best Practices that can be used by oral health care providers to increase the acceptance of the HPV vaccine in a clinical setting. .

5. HPV and Oropharyngeal Cancer

6. HPV • Human papillomavirus (HPV) can cause serious health problems (such as genital warts and certain types of cancers). • In most cases, HPV goes away on its own without causing too many health problems. • Oral HPV is the name given to the HPV found in the mouth and throat.

7. Natural History of HPV Infection • ~80-85% of people acquire any HPV infection at some point in their lives • ~90% of infections clear in 1-2 years in healthy individuals • Almost all cervical cancers are caused by HPV infections that persist more than 2 years.

8. HPV Virology • Mucosal (genital) ~ 40 types • High-risk (HR) HPV strains: HPV16, 18, 31, 45…others • Cervical (70-95%) and other cancers • Low-risk (LR) HPV strains: HPV6, 11….others • Genital warts (>90%) • Cutaneous (skin) / non-mucosal ~60 types • Skin (epithelial) wart • Mainly hands, feet (common in children) • HPV1-4

9. Oral HPV • HPV in mouth and throat • “High Risk”: head and neck cancers • “Low Risk”: warts in the mouth and throat • 7% of people have oral HPV • Only 1% have HPV type 16 (type causes oropharyngeal cancer) • Oral HPV is about 3 times more common in men than in women http://www.cdc.gov/std/hpv/stdfact-hpvandoropharyngealcancer.htm

10. HPV • Every day in the US, about 12,000 people ages 15 to 24 are infected with HPV • Approximately 26 million Americans have an oral HPV infection on any given day • Of those, approximately 2600 are HPV 16 • The fastest growing segment of the oral and oropharyngeal cancer population are otherwise healthy, non-smokers in the 25-50 age range. • When you consider both anatomical sites, HPV is driving the growth in numbers of oral cancers. • http://oralcancerfoundation.org/understanding/hpv/hpv-oral-cancer-facts/

11. HPV-Associated Oropharyngeal Cancer Prevalence • Some cancers of the oropharynx (back of the throat, tongue and tonsils) have been linked with HPV • Recent studies report that about 70% of oropharyngeal cancers are caused by HPV (previously tobacco and alcohol alone) • Approximately 3,100 new cases in females each year in US • 12,638 new cases in males each year in US http://www.cdc.gov/cancer/hpv/statistics/headneck.htm

12. Oral Cavity and Oropharynx

13. Oropharyngeal Cancer Signs/Symptoms • Persistent soar throat • Earaches (usually unilateral and last for a few days) • Hoarseness/persistent sore throat • Enlarged lymph nodes • Pain when swallowing/chewing • Unexplained weight loss • An ulcer or sore that does not heal within 2-3 weeks • A red, white, or black discoloration on the soft tissues in the mouth • Some people may have no signs or symptoms

14. HPV-Associated Oropharyngeal Cancer Rates by Race and Ethnicity http://www.cdc.gov/cancer/hpv/statistics/headneck.htm

15. Racial/Ethnic Disparities • Among whites, about 1.8 women and 8.0 men per 100,000 were diagnosed with HPV-associated oropharyngeal cancer. • Among blacks, about 1.5 women and 6.9 men per 100,000 were diagnosed with HPV-associated oropharyngeal cancer. • Among American Indian/Alaska Natives, about 0.9 women and 4.4 men per 100,000 were diagnosed with HPV-associated oropharyngeal cancer. • Among Asian/Pacific Islanders, about 0.6 women and 2.0 men per 100,000 were diagnosed with HPV-associated oropharyngeal cancer. • Among Hispanics, about 0.9 women and 4.2 men per 100,000 were diagnosed with HPV-associated oropharyngeal cancer. • Among non-Hispanics, about 1.8 women and 8.0 men per 100,000 were diagnosed with HPV-associated oropharyngeal cancer

16. Rates of HPV-Associated Cancers and Median Age at Diagnosis Among Women in the United States, 2004–2008 http://www.cdc.gov/cancer/hpv/statistics/age.htm

17. Rates of HPV-Associated Cancers and Median Age at Diagnosis Among Women in the United States, 2008-2012 http://www.cdc.gov/cancer/hpv/statistics/age.htm

18. Rates of HPV-Associated Cancers and Median Age at Diagnosis Among Men in the United States, 2004–2008 http://www.cdc.gov/cancer/hpv/statistics/age.htm

19. Rates of HPV-Associated Cancers and Median Age at Diagnosis Among Men in the United States, 2008-2012 http://www.cdc.gov/cancer/hpv/statistics/age.htm

20. HPV Attributable Cancer Cases Each Year http://www.cdc.gov/cancer/hpv/statistics/cases.htm

22. Overview • Approximately 70% of oropharyngeal cancers may be linked to HPV • 3100 new cases in females • 12638 new cases in males • Approximately 60% are associated with HPV 16, HPV 18 • Median age at diagnosis for women: 62 yo • Median age at diagnosis for men: 59 yo • White, non-smoking males age 35 to 55 are most at risk, 4 to 1 over females

23. HPV and Nasopharyngeal Cancer

24. Nasopharyngeal Cancer (NPC) • 0.6% of all cancers worldwide • Highest prevalence in Southeast Asia, Southern China, and Northern Africa • Epstein-Barr Virus (EBV) • Recent reports attribute NPC with HPV • Oncogenic HPV is associated with a subgroup of NPC patients, predominantly whites (HPV 16) • No significant difference in survival between patients with HPV + and HPV – NPC

25. Prevention of HPV-related Oropharyngeal Cancer

26. Risk Factors Associated with Oral and Oropharyngeal Cancer • Tobacco • Alcohol • Prolonged sun exposure • HPV • Poor diet/nutrition (low fruit/vegetable intake, Vit A deficiency, chewing betel nuts) • Weakened immune system • Marijuana use

27. U.S. Preventive Services Task Force Issues Draft Recommendation Statement: Screening for Oral Cancer • WASHINGTON, D.C. – April 9, 2013 – The U.S. Preventive Services Task Force (Task Force) today posted a final evidence report and draft recommendation statement on screening for oral cancer • The Task Force found that there is not enough evidence to recommend whether or not primary care professionals should perform oral cancer screenings on all of their adult patients http://www.uspreventiveservicestaskforce.org/bulletins/oralcanbulletin.pdf

28. HPV-Related Oropharyngeal Cancer Soft palate Tongue

29. Screening for Oropharyngeal Cancers • Difficult to detect at early stage (5 yr survival, <50%) • No standardized screening test • No FDA approved test for oral HPV infection • No evidence that detection of oral HPV could be used to predict development of oropharyngeal cancer

30. HPV screening • Oral • Brush biopsy • Histology • Immunohistochemistry • Saliva sampling • PCR • Serology (IgA) • Commercial kits/labs

31. Diagnostic Aids • Tolonium chloride/toluidine blue dye • Oral CDx brush biopsy • Salivary diagnostics • Optical imaging systems

32. HPV Vaccine

33. HPV Vaccines • In 2006, the FDA licensed a quadrivalent vaccine that protects against HPV 6, 11, 16, 18 for females to prevent genital warts and cervical cancer. • In 2009, the FDA licensed a bivalent vaccine that protects against HPV 16 and 18 for females. • In 2009, the quadrivalent vaccine was recommended for use in males to prevent genital warts. • In 2010, the quadrivalent vaccine was approved by the FDA for prevention of anal cancers in males and females. • In 2014, the 9-valent vaccine was approved by the FDA for males and females. [HPV 16, 18, 31,33,45,52,58]

34. HPV Vaccines • Gardasil (Male, Female); genital warts and other types of cancer • Gardasil 9 (Male, Female); genital warts and other types of cancer • Cervarix (Female only); cervical cancer • Recommended 11-12 years of age (males, females) [can be given at age 9] • Female catch up: 13-26 years of age • Male catch up: 13-21 years of age [can go to age 26 if didn’t complete the 3 doses] • ** Advisory Committee on Immunization Practices (ACIP)

35. HPV Vaccine Schedule • According to the Centers for Disease Control and Prevention (CDC), the HPV vaccine has been demonstrated to be safe, effective and offers long lasting protection against HPV-associated cancers. • Most benefit is to complete series before initial exposure to HPV infection. • The number of doses and the time period are dependent upon the age of the recipient when the process begins.

36. HPV Vaccine Schedule • In 2016, new recommendations for use of a 2-dose schedule for girls and boys who initiate the vaccination series at ages 9 through 14 years were published. (2nd dose between 6 and 12 months after the first dose) • Three doses remain recommended for persons who initiate the vaccination series at ages 15 through 26 years and for immunocompromised persons.

37. HPV Vaccine Schedule • Adolescents between 9 through 14 that have received 2 doses of HPV vaccine less than 6 months apart will still require a third dose • The vaccines are most effective when given to children before they become sexually active and are not recommended for anyone with a history of severe allergic reactions to any of the HPV vaccine components or women who are pregnant.

38. HPV Immunization Rates

39. 60% of girls received at least one HPV dose (2015) 42% of boys received at least one HPV dose (2015)

40. Nevada Rates (2015) Immunize Nevada Report • 72% of girls received at least one HPV dose (US: 60%) • 42% of girls received the 3 doses of HPV • 44% of boys received at least one HPV dose (US: 42%) • 24% of boys received the 3 doses of HPV • Healthy People 2020: 80% of 13-15 year olds complete the 3 dose series

41. Source: 2014 National Immunization Survey (NIS) Teen Survey (CDC, 2015) Series Completion: 3 doses by 13th birthday

42. Community and Clinical Linkages

43. Oral Health Care Educators • There is no current practice behavior to council patients on the benefits of HPV vaccine. • Dental health care providers are now being encouraged to become more familiar with HPV and its connection with oropharyngeal cancer. • Dental health care providers play a very important role in the prevention of oral HPV. • Dental providers must have reliable foundation knowledge of basic clinical medicine to safely and effectively treat individuals with chronic and other diseases (health care educators).

44. What Oral Health Care Providers Can Do to Close the Gap • Promote risk-based oral cancer screenings (children/adults) • Talk to parents/caregivers about HPV vaccine (cancer prevention) • Promote integrated health care model • Oral HPV infections need to be studied and investigated thoroughly to help promote HPV awareness in oral health settings.

45. Public/Private Partnerships • Dental school/dental hygiene school curriculum (Higher Ed) • Medical school curriculum (Higher Ed) • Health care providers (dentists, dental hygienists, physicians, pediatricians, physician assistants, nurses, etc.) • Allied health care providers (Community Health Workers, Community Health Nurses) • Community clinics/immunization clinics • Community-based immunization clinics associated with health fairs/back to school fairs

46. Best Practices

47. Medical History • Ask about HPV vaccinations in the medical history (reminders to ask about completion of required doses) • Conduct a thorough oral cancer screening frequently • Discuss HPV and oropharyngeal cancer with patients

50. Association between human papilloma virus (HPV) and Oral Health Christina A. Demopoulos, DDS, MPH1 Tanis Stewart, PhD.2 Marcia Ditmyer, PhD 1§ 1 UNLV School of Dental Medicine, 1001 Shadow Lane, MS 7425, Las Vegas, NV 89106 2 University of Maryland, College Park, MD 20742